
A study analyzing PTEN mutations in indeterminate thyroid nodules found a 25% malignancy risk, with higher rates in Bethesda IV cases (60%) than Bethesda III (16.7%). Based on 23 patients over 8 years, results highlight PTEN mutations as potential markers for thyroid cancer risk stratification.
Like
Save
Share